MorphoSys AG : Antibody Reaches Major Milestone in Collaboration with Roche
06/06/2012| 01:35am US/Eastern
MorphoSys AG /
MorphoSys Antibody Reaches Major Milestone in Collaboration with Roche
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Gantenerumab Clinical Trial Expanded to Pivotal Phase 2/3 Study
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its partner Roche (SIX: RO, ROG; OTCQX: RHHBY) has expanded the ongoing SCarlet RoAD:
http://www.earlysymptomsalzheimers.com/ Phase 2 clinical trial of gantenerumab:
http://www.clinicaltrials.gov/ct2/show/NCT01224106?term=gantenerumab&rank=1 for prodromal (early) Alzheimer's disease to a potentially pivotal study. The trial size will be increased from 360 to 770 participants, and a favorable outcome to the trial could be used by Roche to support a marketing application for gantenerumab. The expansion of the study triggered a clinical milestone payment to MorphoSys, the details of which were not disclosed. MorphoSys stands to receive further developmental milestones as well as royalties on product sales.
"This is a major step forward for a HuCAL antibody program that has genuine blockbuster potential", commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Gantenerumab is the first investigational antibody development program for Alzheimer's disease to be clinically tested in a setting for which there is great hope, namely the treatment of early-stage, pre-dementia subjects. A potential path to market for this program has become much clearer with this transition to a pivotal trial".
"We believe the greater opportunity to make a difference in patients' lives is in early diagnosis and intervention," said Luca Santarelli, Head of Neuroscience at Roche. "Our attempt is to utilize a biomarker-driven approach, leveraging both our pharmaceutical and diagnostics divisions to develop a companion diagnostic for gantenerumab to select patients at the prodromal stage, before significant damage to the brain has occurred."
Gantenerumab is an optimized, fully human antibody that was developed on behalf of Roche by MorphoSys scientists using the Company's proprietary HuCAL:
http://www.morphosys.com/technologies/morphosys-technologies/hucal technology. Gantenerumab is unique amongst antibodies in development in that it binds to both the N-terminus and mid-section of the 42 amino acid amyloid-β peptide. It has been shown to break down amyloid plaque both in vitro and in vivo. In Phase 1 clinical trials conducted by Roche1), the antibody was found to bring about rapid, dose-dependent clearance of plaque from the brains of mild to moderate Alzheimer's disease patients. The ongoing clinical trial is designed to evaluate its effect on cognition and functioning as well as its safety and pharmacokinetics in patients with prodromal, or early-stage, Alzheimer's disease. In this phase of the disease, which can be characterized by measuring certain biomarkers, patients have only mild cognitive impairment and have not yet been diagnosed with Alzheimer's disease. According to recent research, amyloid plaque may accumulate even at this early stage in the brains of sufferers, and may lead to full-blown disease.
MorphoSys's clinical pipeline now comprises one program in phase 3 development, seven in phase 2 and twelve in phase 1. Of these, four are proprietary, as yet un-partnered programs, namely MOR103, which is in a phase 1b/2a trial for rheumatoid arthritis and a phase 1b trial in multiple sclerosis, MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.
1) Reference: Ostrowitzki, S. et al (2011) Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Archives of Neurology, 68(10); http://archneur.ama-assn.org/cgi/content/full/archneurol.2011.1538:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec:
http://www.abdserotec.com/ unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE